Abstract:The search for new metal-based anticancer drug candidates is a fundamental task in medicinal inorganic chemistry. In this work, we assessed the potential of two new Ru( II )–phosphine–mercapto complexes as potential anticancer agents. The complexes, with the formula [Ru(bipy)(dppen)(Lx)]PF 6 [( 1 ), HL1 = 2-mercapto–pyridine and ( 2 ), HL2 = 2-mercapto–pyrimidine, bipy = 2,2′-bipyridine, dppen = cis -1,2-bis(diphenylphosphino)-ethylene] were synthesized and characterized by nuclear magnetic resonance (NMR) [ 1 H, 31 P( 1 H), and 13 C], high resolution mass spectrometry (HR-MS), cyclic voltammetry, infrared and UV-Vis spectroscopies. Complex 2 was obtained as a mixture of two isomers, 2a and 2b , respectively. The composition of these metal complexes was confirmed by elemental analysis and liquid chromatography-mass spectrometry (LC-MS). To obtain insights into their lipophilicity, their distribution coefficients between n -octanol/PBS were determined. Both complexes showed affinity mainly for the organic phase, presenting positive log P values. Also, their stability was confirmed over 48 h in different media ( i.e. , DMSO, PBS and cell culture medium) via HPLC, UV-Vis and 31 P{ 1 H} NMR spectroscopies. Since enzymes from the P-450 system play a crucial role in cellular detoxification and metabolism, the microsomal stability of 1 , which was found to be the most interesting compound of this study, was investigated using human microsomes to verify its potential oxidation in the liver. The analyses by LC-MS and ESI-MS reveal three main metabolites, obtained by oxidation in the dppen and bipy moieties. Moreover, 1 was able to interact with human serum albumin (HSA). The cytotoxicity of the metal complexes was tested in different cancerous and non-cancerous cell lines. Complex 1 was found to be more selective than cisplatin against MDA-MB-231 breast cancer cells when compared to MCF-10A non-cancerous cells. In addition, complex 1 affects cell morphology and migration, and inhibits colony formation in MDA-MB-231 cells, making it a promising cytotoxic agent against breast cancer.

Antimetastatic activity of (arene)ruthenium(II) complex of 4-aryl-4H-naphthopyran

Ruthenium(II) Complexes with 2-Phenylimidazo[4,5-f][1,10]phenanthroline Derivatives that Strongly Combat Cisplatin-Resistant Tumor Cells

Selective anticancer activities of ruthenium(II)-tetrazole complexes and their mechanistic insights

Antiangiogenic Ruthenium(ii) Benzimidazole Complexes, Structure-Based Activation of Distinct Signaling Pathways

Mechanistic Studies of Arene-Ruthenium(II) Complexes with Carbothioamidopyrazoles as Alternative Cancer Drugs

Ruthenium(II)-N-alkyl phenothiazine complexes as potential anticancer agents

Arene Ruthenium(Ii) Complexes As Low-Toxicity Inhibitor Against the Proliferation, Migration, and Invasion of Mda-Mb-231 Cells Through Binding and Stabilizing C-Myc G-Quadruplex Dna

Exploring the potential of ruthenium(ii)–phosphine–mercapto complexes as new anticancer agents

Anticancer and antimicrobial properties of novel η6- p-cymene ruthenium(ii) complexes containing a N,S-type ligand, their structural and theoretical characterization

Ru(II)‐Nitrophenylhydrazine/Chlorophenylhydrazine Complexes: Nanoarchitectonics, Biological Evaluation and In silico Study

Synthesis, Cytotoxicity and Anti‐metastatic Properties of New Pyridyl–thiazole Arene Ruthenium(ii) Complexes

Cytotoxicity in vitro, cellular uptake, localization and apoptotic mechanism studies induced by ruthenium(II) complex

Ruthenium complexes with ABIRATERONE acetate as ANTIPROLIFERATIVE agents

Effective and Selective Ru(II)-Arene Complexes Containing 4,4'-Substituted 2,2' Bipyridine Ligands Targeting Human Urinary Bladder Cancer Cells

Study on antitumor activity of three ruthenium arene complexes in vitro

Cytotoxic Cis-Ruthenium(iii) Bis(amidine) Complexes.

Ruthenium compounds: Are they the next‐era anticancer agents?

Dinuclear Organoruthenium Complexes Exhibiting Antiproliferative Activity Through DNA Damage and a Reactive-Oxygen-Species-Mediated Endoplasmic Reticulum Stress Pathway.

Synthesis, characterization, and anticancer activity of dithiocarbamate ruthenium(II) complexes

A Ruthenium(ii) Complex Inhibits Tumor Growth in Vivo with Fewer Side-Effects Compared with Cisplatin

Synthesis, characterization, and antitumor activity of mononuclear and dinuclear ruthenium complexes